Baxter Investors Face Dec. 15 Lead-Plaintiff Deadline in Novum Pump Securities Suit

Plaintiffs say Baxter concealed systemic Novum pump defects, with a later shipment halt triggering a sharp stock drop.

Overview

Investors have until December 15, 2025 to seek appointment as lead plaintiff in the federal securities case.
The putative class covers purchases of Baxter securities from February 23, 2022 through July 30, 2025.
The complaint alleges the Novum large‑volume infusion pump malfunctioned through underinfusion, overinfusion, and non‑delivery, creating risks of serious injury or death.
Filings contend Baxter received reports of malfunctions, injuries, and deaths and that customer alerts were inadequate while design issues persisted.
On July 31, 2025, Baxter paused Novum shipments and planned installations without a restart date, and the stock fell about 22.4% as law firms including Faruqi & Faruqi, Levi & Korsinsky, and the Law Offices of Howard G. Smith now solicit investors.